Palo Santo is a venture capital firm that focuses on investing in the psychedelic healthcare sector to address the global mental health crisis. Their strategy involves funding a diverse range of psychedelic-focused businesses, including biopharma, drug development, digital therapeutics, healthcare services, and tech-enabled solutions, with a particular emphasis on novel chemical entities and early-stage companies.
50% of their portfolio is in Healthcare. Their most common stage is series-a (50% of deals). Average disclosed round size is $41.9M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$55M
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RReunion Neuroscience Inc. | Series A | $103M | May 2024 |
 Journey Clinical | Series A | $8.5M | Jan 2023 |
 Gilgamesh Pharmaceuticals | Series B | $39M | Dec 2022 |
 Sensorium Therapeutics | Series A | $30M | Nov 2022 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| Journey Clinical | Seed | $3M | Sep 2021 |
 Beckley Psytech | Series B | $80M | Aug 2021 |
| KKsana Health | Seed | $2M | Jun 2021 |
Top Co-Investors
PsyMed3 shared
Able Partners2 shared
Prime Movers Lab2 shared
Fifty Years2 shared
Route 66 Ventures2 shared
Panoramic1 shared
RA Capital Management1 shared
Apeiron Investment Group1 shared
Casa Verde Capital1 shared
Dolby Family Ventures1 shared
Presight Capital1 shared
The Vertical Group1 shared
Adage Capital Management1 shared
Re.Mind Capital1 shared
MPM BioImpact1 shared
Novo Holdings1 shared
Arkin Bio Ventures1 shared
Plaisance Capital Management1 shared
Union Square Ventures1 shared
AlleyCorp1 shared
Last updated: 12 April 2026